James M. Frincke, Chief Scientific Officer at HOLLIS EDEN PHARMACEUTICALS INC /DE/ (HEPH), sold 1,125 shares at $5.76 ($6K) on 2007-02-13, disclosed to the SEC on 2007-02-15.
Scheduled sale ($6k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.68 | 337 | $2K | 29.9% |
| 2 | $5.69 | 451 | $3K | 40.0% |
| 3 | $5.71 | 225 | $1K | 20.0% |
| 4 | $5.76 | 112 | $645 | 10.1% |
| Total | $5.70 avg | 1,125 | $6K | 100% |
| Filing → |